Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges

Table 1 Overall survival results of study based meta-analyses comparing post-operative chemotherapy vs surgery alone

Ref.	Studies analysed (n)	Pooled HR (95%CI)
Earle et al[16]	13	0.80 (0.66-0.97)
Mari et al[17]	20	0.82 (0.75-0.89)
Janunger et al[19]	21	0.84 (0.74-0.96)
Oba et al[20]	4	0.73 (0.60-0.89)
Liu et al[21]	19	0.85 (0.80-0.90)
Zhao et al[22]	15	0.90 (0.84-0.96)
Sun et al[23]	12	0.78 (0.71-0.85)

Table 2 GASTRIC group meta-analysis[10]

Studies (n)		Comparison	Pooled HR (95%CI)
For OS analysis	For DFS analysis1		OS	DFS
17	14	Overall	0.82 (0.76-0.90)	0.82 (0.75-0.90)
2	1	Mono Chemotherapy vs surgery	0.60 (0.40-0.84)	0.49 (0.29-0.84)
3	2	Fluorouracil + mitomycin C + other without anthracyclines vs surgery	0.74 (0.58-0.95)	0.69 (0.48-0.98)
3	2	Fluorouracil + mitomycin C + anthracyclines vs surgery	0.82 (0.71-0.95)	0.80 (0.69-0.94)